Michael Makris: How Haemophilia Care Is Delivered in China
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, reposted from RPTH Journal on LinkedIn:
”If you would like to know how haemophilia care is delivered in China then have a look at this paper.”
Quoting RPTH Journal‘s post about a recent article by Yun Wang et al, adding:
”Inherited bleeding disorders in China: a rapidly evolving therapeutic and healthcare landscape
With over 1.4 billion people, China faces a growing demand for the diagnosis and treatment of inherited bleeding disorders (IBDs), particularly haemophilia.
A new review in RPTH Journal takes stock of the remarkable progress made in recent years and the road ahead.
Key highlights:
- China is rapidly expanding its domestic manufacturing capacity for IBD therapeutics, from basic replacement therapies to advanced treatments including gene therapy
- A tiered healthcare system for haemophilia is being developed to optimise resource allocation and standardise care across both rural and urban areas
- A diverse pipeline of investigational domestic novel drugs is under active development
- The goal: more efficient, cost-effective, and accessible care for patients nationwide
This review offers a comprehensive overview of where China stands today, and where it is headed, in the management of inherited bleeding disorders.
The combination of domestic drug innovation and an evolving healthcare delivery system could significantly improve outcomes and quality of life for patients across the country.”
Title: The therapeutic landscape of inherited bleeding disorders in China
Authors: Yun Wang, Feng Xue, Man-Chiu Poon, Renchi Yang
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment
-
Oct 19, 2026, 16:04Hussnain Javaid: New EHA Guidelines for HbSC Disease Management
-
Oct 19, 2026, 15:50Deep Madkaiker: A New Academic Opportunity in Transfusion Medicine at ACTREC
-
Oct 19, 2026, 15:19Why Hematologists Should Care About Diminished Ovarian Reserve in SCD – ASH Education
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening